March 8th 2024
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
February 27th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Partially Halts Phase I Study of ACTR707 in Non-Hodgkin Lymphoma
March 12th 2020The FDA has placed a partial clinical hold on the phase I trial of ACTR707 in combination with rituximab in patients with relapsed/refractory B-cell lymphoma from Unum Therapeutics, following the submission of a safety report from the company. The FDA notified Unum of the hold verbally on March 4. Unum Therapeutics acknowledged the partial clinical hold in filings with the Securities and Exchange commission.
Read More
Careful Data Review Recommended for Upfront Treatment Selection in iNHL
February 29th 2020To enhance outcomes for patients with indolent non-Hodgkin lymphoma, an in-depth review of the available data is required. As a start, Sonali M. Smith, MD, University of Chicago Medicine, reviewed the clinical trial findings that are currently informing treatment selection in the frontline iNHL paradigm, at 24th Annual International Congress on Hematologic Malignancies.
Read More
Evaluation of an expansion cohort of the pivotal phase I/II ZUMA-1 trial in patients with refractory large B-cell lymphoma revealed that early steroid intervention may have a positive impact on the toxicity profile of chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel, according to findings presented during a poster session at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Read More
Investigational Bispecific Antibody Signals Safety and Efficacy in B-Cell NHL
January 14th 2020In an interview with Targeted Oncology, Rajat Bannerji, MD, PhD, discussed the safety and efficacy findings from the phase I trial of a bispecific antibody in patients with heavily pretreated NHL, including cohorts of patients with follicular lymphoma and diffuse large B-cell lymphoma.
Read More
High Rates of CR Observed in Follicular Lymphoma With Triplet Regimen
December 8th 2019Patients with relapsed/refractory follicular lymphoma showed durable responses with the combination of polatuzumab-vedotin, obinutuzumab, and lenalidomide, according to results presented at the 2019 ASH Annual Meeting.
Read More
Obinutuzumab Plus Lenalidomide Shows Promise in High Tumor Burden Follicular Lymphoma
December 8th 2019Obinutuzumab combined with lenalidomide resulted in early and very high complete response rates in previously untreated patients with follicular lymphoma in a single-center phase II study. At a median follow-up of 25 months, the 2-year progression-free survival was 96%.
Read More
Weighing Treatment Options in Newly Diagnosed Follicular Lymphoma
November 7th 2019Deciding between a watch-and-wait approach and systemic therapy in patients with newly diagnosed follicular lymphoma should be carefully assessed based on specific disease characteristics, with follow-up tailored toward patients’ risk of relapse, according to John P. Leonard, MD.
Read More
Umbralisib Monotherapy Reaches ORR End Point in Follicular Lymphoma Population of Pivotal NHL Trial
October 31st 2019Umbralisib monotherapy demonstrated positive responses in patients with previously treated follicular lymphoma, meeting the primary end point for the follicular lymphoma cohort of the phase IIb UNITY-NHL trial, TG Therapeutics announced in a press release.
Read More